The dental membrane and bone graft substitute market consists of various products that aid in guided bone regeneration and guided tissue regeneration during dental surgical procedures. Membranes, whether resorbable or non-resorbable, act as a barrier between the bone and gum tissues to allow new bone growth while preventing soft tissues from growing into the bone defect site. Bone graft substitutes, on the other hand, help in filling up bone voids, defects, or gaps and promote new bone formation. They are available in various forms such as granules, gel, putty, strips, and sheets. These products are widely used in dental implant procedures, sinus lifting procedures, ridge augmentation, and socket preservation procedures. They provide better aesthetic results and faster healing compared to traditional procedures.
The global dental membrane and bone graft substitute market is estimated to be valued at US$ 1,045.3 M in 2024 and is expected to exhibit a CAGR of 9.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Technological advancements continue to revolutionize the dental membrane and bone graft substitute market. Researchers are developing novel bone graft materials that can induce faster bone regeneration. For instance, companies are developing bioactive bone graft substitutes with osteoinductive, osteoconductive, and osteogenic properties to closely mimic natural bone. They contain mineralized collagen or bioceramic crystals that can induce stem cells into osteoblast lineage for new bone formation. Additive manufacturing techniques like 3D printing are also being utilized to fabricate custom-shaped bone grafts matching complex defects and anatomical sites. Apart from biomaterial innovation, computer-guided surgical procedures using CBCT imaging and surgical guides/templates ensure precise bone regeneration outcomes. Rising awareness about dental aesthetics and implants is a key growth driver for dental membrane and bone graft substitutes.
Threat of new entrants: The threat of new entrants in the dental membrane and bone graft substitute market is moderate. Significant capital investment is required to conduct research and development activities for developing new dental membrane and bone graft substitute products.
Bargaining power of buyers: The bargaining power of buyers is moderate. Buyers can negotiate on the pricing and quality of dental membrane and bone graft substitute products. However, switching costs are high as buyers need to consider compatibility and regulatory issues.
Bargaining power of suppliers: The bargaining power of suppliers is low to moderate. Few major players operate in the supply of raw materials for dental membrane and bone graft substitute products. However, suppliers still have bargaining power in terms of supply and consistent quality of materials.
Threat of new substitutes: The threat of new substitutes is low as currently, there are limited product substitutes available for dental membrane and bone graft substitute products.
Competitive rivalry: The competitive rivalry is high as the global dental membrane and bone graft substitute market includes numerous international and domestic players. Players compete based on product quality, innovation, and pricing.
The global dental membrane and bone graft substitute market is expected to witness high growth over the forecast period. The market for dental membrane and bone graft substitute is expected to grow at a CAGR of 9.4% to reach a value of US$ 1,045.3 million by 2024.
North America is expected to dominate the global dental membrane and bone graft substitute market during the forecast period. Factors such as growing prevalence of dental diseases, availability of advanced treatment options, and favorable reimbursement policies are driving the growth of the market in the region.
Key players operating in the dental membrane and bone graft substitute market are Geistlich Pharma AG, Zimmer Biomet Holdings, Inc., Dentsply Sirona Inc., Medtronic Plc, Institut Straumann AG. Players are focusing on new product approvals and launches to strengthen their market position. For instance, in July 2021, Geistlich Pharma AG received FDA approval for its bone graft substitute product, Bio-Oss Collagen.
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it